

NYRx Coverage Overview of Glucagon Like Peptide-1 Receptor Agonists

September 21, 2026

NYRx, the Medicaid Pharmacy Program covers GLP-1 Receptor Agonists for those who have type 2 diabetes, to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and obesity, and those with moderate to severe obstructive sleep apnea (OSA) with obesity.

GLP-1s remain [excluded from coverage](#) when used for the treatment of weight loss.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Type 2 Diabetes

[NYRx Drug Class Coverage Overview: Glucagon-Like Peptide-1 \(GLP-1\) Receptor Agonists – Type 2 Diabetes](#)

Preferred Drugs	Non-Preferred Drugs	Coverage Parameters
VI. Endocrine and Metabolic Agents		
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists – Type 2 Diabetes CC		
exenatide Ozempic® pen Trulicity® Victoza® BLTG	liraglutide (gen Victoza®) Mounjaro® Ozempic® tablets Rybelsus® Soliqua® Xultophy®	CLINICAL CRITERIA (CC) - Confirm diagnosis of FDA-approved or compendia-supported indication and Medicaid covered indication - PA required for patients utilizing a GLP-1 and DPP-IV concurrently

Major Adverse Cardiovascular Events (MACE)

[NYRx Drug Coverage Overview: Wegovy®](#)

Drug / Class Name	Step Therapy (ST) Parameters	Frequency / Quantity / Duration (F/Q/D) Parameters	Additional / Alternate Parameter(s)
semaglutide (Wegovy®)		LIFETIME QUANTITY LIMIT: Two treatment attempts per lifetime	- Confirm diagnosis of cardiovascular disease - Confirm patient BMI of $\geq 40\text{kg/m}^2$ - Confirm patient is participating in lifestyle modifications that support cardiovascular health



Obstructive Sleep Apnea (OSA)

[NYRx Drug Coverage Overview: Zepbound®](#)

Drug / Class Name	Step Therapy (ST) Parameters	Frequency / Quantity / Duration (F/Q/D) Parameters	Additional / Alternate Parameter(s)
tirzepatide (Zepbound®)		LIFETIME QUANTITY LIMIT: Two treatment attempts per lifetime	- Confirm diagnosis of obstructive sleep apnea (OSA) - Confirm patient BMI of $\geq 40\text{kg/m}^2$ - Confirm patient is participating in lifestyle modifications

Resources

- [NYRx Drug Class Coverage Overview: Glucagon-Like Peptide-1 \(GLP-1\) Receptor Agonists – Type 2 Diabetes](#)
- [NYRx Drug Coverage Overview: Wegovy®](#)
- [NYRx Drug Coverage Overview: Zepbound®](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Excluded Diagnoses](#)
- [NYRx Preferred Drug List](#)
- [NYRx Prior Authorization Form](#)
- [NYRx Prior Authorization Submission Guide](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.